興齊眼藥(300573.SZ)收到藥品補充申請批件
格隆匯7月15日丨興齊眼藥(300573.SZ)宣佈,公司於近日收到國家藥監局下發的關於鹽酸莫西沙星滴眼液的藥品註冊受理通知書。
鹽酸莫西沙星滴眼液公司研發代碼為SQ-735M,申報的臨牀適應症為:用於治療敏感微生物引起的細菌性結膜炎。該次申請是在公司鹽酸莫西沙星滴眼液(國藥準字H20213266)基礎上進行的補充申請。
目前,國內已有多家鹽酸莫西沙星滴眼液上市。原研藥品由美國Alcon公司生產,為多劑量眼用製劑,現已進入中國。鹽酸莫西沙星滴眼液為國家醫保目錄乙類產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.